Abstract 1925
Background
Limited researches evaluate effectiveness of cancer patients-centered home care management. In this context, patients’ needs rather than prognosis should be considered. Our project represents an opportunity for patients who may benefit from chemotherapy, but with physical and social problems that prevent day-hospital access, and a model of no profit contribution to the Public Health System.
Methods
Our Medical Oncology Department, supported by a no-profit organization and according to the GP, conducted the project from May 2014 to March 2019. We included frail patients selected with G8 score (<14), with advanced disease, treated with oral, subcutaneously or parenteral biological agents, with limitations to day-hospital access, comorbidities and at least six months life expectancy. A multidisciplinary team, coordinated by three oncologists, included also four nurses, a pain therapist, a psychologist and a physiotherapist. Satisfaction was evaluated with the FAMCARE scale.
Results
A total of 161 patients (median age of 71 years, range 38-93), were enrolled. Ninety percent of patients had metastatic disease and median G8 score of 8.8 (2.5-13.5). All of them received home cancer treatments and concomitant supportive cares, if necessary; 24 patients received two or more lines of cancer treatment. Considering 148 concluded taking care, median time was 175 days (7-1200). A median number of 254 (195-325) nursing home visits and 164 (139-190) medical home visits were performed each year, with an average of 1.6 and 1.1 visits per month per patient, respectively. Median number of in-line patients was 20 (17-25). Hospitalization occurred in 19.3%. Home blood transfusions were delivered in 6 patients, paracentesis in 8. One third of them died at home. FAMECARE assessed high satisfaction.
Conclusions
Our experience demonstrates that the integration of home cancer treatment and supportive care is feasible and effective. Hospitalization rate is lower than data reported in literature. If confirmed in perspective pharmaco-economics studies, our data suggest that home cancer treatments provide high quality assistance to frail patients. Integration with no-profit organization was successful. Our model could be applied in other settings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3620 - Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours
Presenter: Wolfgang Wick
Session: Poster Display session 1
Resources:
Abstract
5465 - Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
Presenter: Manuel Hidalgo
Session: Poster Display session 1
Resources:
Abstract
2555 - A Phase 1a/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumors
Presenter: John Sarantopoulos
Session: Poster Display session 1
Resources:
Abstract
3533 - First in human phase 1/2a study of PEN-866, a Heat Shock Protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumors: Phase 1 results
Presenter: Johanna Bendell
Session: Poster Display session 1
Resources:
Abstract
4114 - A Phase I Open-Label, Non-Randomized Study of Recombinant Super-Compound Interferon (rSIFN-co) In Patients with Advanced Solid Tumors
Presenter: Amanda Seet
Session: Poster Display session 1
Resources:
Abstract
2537 - Evaluation of Pharmacodynamic (PD) Biomarkers in Advanced Cancer Patients Treated with Oxidative Phosphorylation (OXPHOS) Inhibitor, OPC-317 (OPC)
Presenter: Jie Qing Eu
Session: Poster Display session 1
Resources:
Abstract
5764 - Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumours
Presenter: Natalie Cook
Session: Poster Display session 1
Resources:
Abstract
2683 - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumors.
Presenter: Wael Harb
Session: Poster Display session 1
Resources:
Abstract
3609 - Interim Results from Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors
Presenter: Judy Wang
Session: Poster Display session 1
Resources:
Abstract
3485 - Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase
Presenter: Andrea Wang-Gillam
Session: Poster Display session 1
Resources:
Abstract